Business
ORYZON Receives European Medicines Agency Approval to Initiate a Phase Ib Study of Iadademstat in Sickle Cell Disease
First iadademstat clinical trial in non-malignant hematological indications MADRID and CAMBRIDGE, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, Ticker: ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, today announced that the European Medicines Agency (EMA) has approved its Clinical Trial Application (CTA), the European equivalent to an IND, to initiate a Phase Ib trial of iadademstat in sickle cell disease (SCD). T
About this update from Oryzon Genomics Sa
[{"type":"image","alt":"Oryzon Genomics, S.A.","displaySize":"","headline":null,"caption":"Oryzon Genomics, S.A.","className":"","disableSlideshowImg":false,"size":{"original":{"width":182,"height":70,"url":"https://media.zenfs.com/en/globenewswire.com/371936053f3f3aceeaf8ca929a3547e2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/cNdaqSWVXmpOQnfrePXGFw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTEzODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/371936053f3f3aceeaf8ca929a3547e2","width":182,"height":70}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"First iadademstat clinical trial in non-malignant hematological indications","length":75,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":75,"olType":false},{"type":"text","content":"MADRID and CAMBRIDGE, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, Ticker: ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, today announced that the European Medicines Agency (EMA) has approved its Clinical Trial Application (CTA), the European equivalent to an IND, to initiate a Phase Ib trial of iadademstat in sickle cell disease (SCD). This will be the first clinical trial investigating iadademstat in a non-malignant hematological indication.","length":531,"tagName":"p"},{"type":"text","content":"The Phase Ib study, named RESTORE (REgulation of Sickling ThrOugh Reprogramming Epigenetics), will be conducted at multiple sites in Spain and aims to enroll 40 adult patients with SCD. The trial’s primary objectives will be to evaluate the safety and tolerability of iadademstat and to establish its Recommended Phase 2 dose (RP2D). Secondary objectives include assessing iadademstat’s activity to induce fetal hemoglobin (HbF), among others.","length":443,"tagName":"p"},{"type":"text","content":"SCD is a chronic, inherited blood disorder caused by a mutation in the β-globin gene, leading to the production of hemoglobin S (HbS) instead of the normal hemoglobin A. Under low oxygen conditions, HbS tends to polymerize, causing red blood cells to assume a sickle shape, becoming rigid and fragile. This results in microvascular occlusion, hemolysis, and chronic inflammation.","length":379,"tagName":"p"},{"type":"text","content":"The clinical manifestations of SCD include vaso-occlusion and hemolytic anemia, which lea...